Recent Quotes (30 days)

You have no recent quotes
chg | %

Labopharm Inc.  

(Public, TSE:DDS)   Watch this stock  
Find more results for DDS
0.0000
- Close
TSE data delayed by 15 mins - Disclaimer
Currency in
Range     -
52 week 0.13 - 1.06
Open     -
Vol / Avg. 0.00/256,821.00
Mkt cap 20.40M
P/E     -
Div/yield     -
EPS -0.32
Shares     -
Beta 0.98
Inst. own     -

Key stats and ratios

Q2 (Jun '11) 2010
Net profit margin 21.12% -8.30%
Operating margin 21.12% -7.64%
EBITD margin - 5.34%
Return on average assets 13.99% -6.37%
Return on average equity - -
Employees 130 -
CDP Score - -

Address

102, 6111 av. Royalmount
MONTREAL, QC H4P2T4
Canada

Website links

Description

Labopharm Inc. is an international, specialty pharmaceutical company focused on optimizing the performance of existing drugs by incorporating its advanced controlled-release technologies. The Company�s lead product, a once-daily formulation of the analgesic tramadol, is being commercialized internationally and it focuses to pursue additional launches in markets around the world. Its second product, OLEPTRO, a once-daily formulation of trazodone (a serotonin antagonist reuptake inhibitor) for the treatment of major depressive disorder (MDD) has received regulatory approval from the United States Food and Drug Administration (FDA) and is in the process of finalizing the commercialization plan for its product. It is also developing a series of abuse- and misuse-deterrent products based on its Contramid-based technology platform. In addition, it has other products in development utilizing its Contramid or its polymeric nano-delivery system (PNDS) technologies.